Humacyte Clinical Results in High-Risk Dialysis Patients from V007 Pivotal Phase 3
DURHAM, N.C., June 02, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, announced that its abstract on the V007 Pivotal Phase 3 clinical trial of the acellular tissue engineered vessel (ATEV™) in arteriovenous access for high-risk patients with end-stage renal disease was accepted for an oral presentation at the Society for Vascular Surgery Vascular Annual Meeting (VAM25). The abstract titled 'Acellular Tissue Engineered Vessel Outperforms Arteriovenous Fistula in High-Risk Patients on Hemodialysis: Results from the CLN-PRO-V007 Randomized Controlled Trial' will be presented at the VAM25 meeting in New Orleans this Friday, June 6, 2025.
Details of the presentation are as follows:
Presentation Title: 'Acellular Tissue Engineered Vessel Outperforms Arteriovenous Fistula in High-Risk Patients on Hemodialysis: Results from the CLN-PRO-V007 Randomized Controlled Trial'
Presenter: Dr. Mohamad A. Hussain, MD, PhD, RPVI, FAHA, FRCSC, FACS, Vascular and Endovascular Surgeon-Scientist at Brigham and Women's Hospital, Core Faculty at the Center for Surgery and Public Health, and Assistant Professor of Surgery at Harvard Medical School
Session Title: Plenary Session 6
Session Date/Time: Friday, June 6, 2025, 10:50 a.m. CT
For more information on the Society for Vascular Surgery Vascular Annual Meeting (VAM25), please click here.
About Humacyte
Humacyte, Inc. (Nasdaq: HUMA) is developing an innovative biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues designed to treat a wide range of diseases, injuries, and chronic conditions. Humacyte's Biologics License Application for the acellular tissue engineered vessel (ATEV) in the vascular trauma indication was approved by the FDA in December 2024. ATEVs are also currently in late-stage clinical trials targeting other vascular applications, including arteriovenous (AV) access for hemodialysis and peripheral artery disease (PAD). Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte's 6mm ATEV for AV access in hemodialysis was the first product candidate to receive the FDA's Regenerative Medicine Advanced Therapy (RMAT) designation and has also received FDA Fast Track designation. Humacyte's 6mm ATEV for urgent arterial repair following extremity vascular trauma and for advanced PAD also have received RMAT designations. The ATEV received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense. For more information, visit www.Humacyte.com.
For uses other than the FDA approval in the extremity vascular trauma indication, the ATEV is an investigational product and has not been approved for sale by the FDA or any other regulatory agency.
Humacyte Investor Contact:
Joyce Allaire
LifeSci Advisors LLC
+1-617-435-6602
[email protected]
[email protected]
Humacyte Media Contact:
Rich Luchette
Precision Strategies
+1-202-845-3924
[email protected]
[email protected]
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
30 minutes ago
- Medscape
Patients With HS, Obesity Report Improvements With GLP-1 RAs
In a survey of 22 patients with hidradenitis suppurativa (HS), more than two thirds reported symptom improvement after treatment with glucagon-like peptide 1 receptor agonists (GLP-1 RAs). METHODOLOGY: Researchers conducted a cross-sectional survey of 22 adults (average age, 45 years; 90.9% women) with HS who were treated with GLP-1 RAs at the University of Pennsylvania's Dermatology Department between January 2019 and August 2024. Most participants were non-Hispanic (90.9%), 54.5% were Black, and 36.4% were White; 89.5% were classified as overweight or having obesity. GLP-1 RAs prescriptions were semaglutide (40.9%), tirzepatide (36.4%), dulaglutide (18.2%), or liraglutide (4.5%), with an average treatment duration of 17 months (range, 2-108 months). Primary outcomes were HS severity and quality of life. TAKEAWAY: Most participants (77.3%) achieved weight loss averaging 31 lb; 68.2% reported improvement in HS-specific health, while 31.8% reported no change in their condition. Patient-reported symptom improvements included reduced flares (61.9%), new lesions (66.7%), pain (52.4%), drainage (61.9%), itch (47.6%), and odor (42.9%). Common side effects included gastrointestinal symptoms, allergic reactions, headaches, menstrual spotting, and appetite suppression. Nearly 60% of patients reported that HS had less impact on their daily activities, with the same percentage stating they would recommend GLP-1 RAs to other patients. IN PRACTICE: 'These data suggest GLP-1 RAs may play an important adjunctive role in the treatment of HS, particularly given the high prevalence of obesity and diabetes in the HS population,' the study authors wrote. 'Randomized controlled studies with robust patient and dermatologist-reported endpoints,' they added, 'are needed to confirm these findings and establish clinical guidelines for use of GLP-1 RAs' in HS. SOURCE: The study was led by Radhika Gupta, BA, University of Pennsylvania, Philadelphia. It was published online on May 29 in JAAD International . LIMITATIONS: Study limitations included small size, lack of clinician assessment, high nonresponse rate, and potential recall bias. DISCLOSURES: The study received funding through a philanthropic gift for HS research. Gupta disclosed being a consultant for Cabaletta Bio. One author reported receiving research funding from Amgen, Boehringer Ingelheim, Cabaletta Bio, and InflaRx. Another author reported being a consultant for Sonoma Biotherapeutics, and the fourth author reported being a consultant for Vertex Pharmaceuticals.
Bloomberg
44 minutes ago
- Bloomberg
Germany's Merz to Meet Trump in Washington
German Chancellor Friedrich Merz will travel to Washington for his inaugural meeting with US President Donald Trump on Thursday. With just weeks until Trump has threatened to implement sweeping 50% tariffs on all European goods, the timing of Merz's trip is critical. Bloomberg's Michael Nienaber reports. (Source: Bloomberg)
CBS News
an hour ago
- CBS News
Sacramento to release 400,000 sterile mosquitoes to fight off invasive ones
Sacramento aims to fight off invasive mosquitoes by releasing thousands more Sacramento aims to fight off invasive mosquitoes by releasing thousands more Sacramento aims to fight off invasive mosquitoes by releasing thousands more SACRAMENTO — Sacramento is launching a new tactic to stop the spread of invasive mosquitoes that can infect people with Zika and dengue fever. The plan, which was just approved by the Environmental Protection Agency, is to release 400,000 live mosquitoes into the environment. "We need ways to combat these mosquitoes, which are posing a public health threat," said Luz Maria Robles with the Sacramento Yolo Mosquito and Vector Control District. The swarm will initially be released across 100 acres of Sacramento's south Natomas neighborhood, which has been the biggest breeding ground. To ensure the mosquitoes are safe for the public, only sterile males will be used in the program. "Male mosquitoes do not bite, so while you might see more mosquitoes than usual, we want those males to mate with the wild females because once they do, their eggs will not hatch," Robles said. Fresno's consolidated mosquito district was the first in California to use this technique, and they say data shows it is safe and effective. "We had tremendous success with that program in the areas where we did release," said Jodi Holeman, manager of the Fresno abatement district. "We got in excess of 98% suppression." If successful in south Natomas, releases could occur in other Sacramento neighborhoods, Robles said. The Sacramento Yolo Mosquito and Vector Control District says it will cost about $33,000 to purchase the mosquitoesnd the releases are scheduled to begin on july 8th.
